Galera Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies to improve the lives of cancer patients. The company's primary focus is on addressing the side effects of radiation therapy and chemotherapy, which can often lead tosevere tissue damage and inflammation.

Galera's lead product candidate is GC4419, a potent and highly selective small mole culedismutase mimetic designed to reduce the incidence and severity of radiation-induced severeoral mucositis (SOM). Oral mucositis is a common and debilitating side effect of radiation therapy for head and neck cancer, causing pain, difficulty swallowing, and increased risk of infection.

GC4419 works by mimicking the activity of superoxide dismutase, an enzyme that protects cellsfrom oxidative stress. By reducing oxidative damage to healthy tissues, GC4419 has the potential to mitigate the development of severe oral mucositis and improve patient outcomes.

Galera Therapeutics has conducted several clinical trials evaluating the safety and efficacy ofGC4419 in patients undergoing radiation therapy for head and neck cancer. Results from the sestudies have shown promising outcomes, with GC4419 demonstrating significant reductions in the incidence and duration of severe oral mucositis compared to placebo.

In addition to GC4419, Galera Therapeutics is also exploring the potential of its dismutasemimetic technology in other indications, such as reducing the incidence of radiation-induced pulmonary toxicity in lung cancer patients.

Overall, Galera Therapeutics is dedicated to advancing the development of novel therapies that address unmet medical needs in cancer treatment, particularly focusing on improving the quality of life for patients undergoing radiation therapy and chemotherapy.